Giri Research

Veda N. Giri, MD

Contact

Name: Veda N. Giri, MD
Position: Associate Professor

1025 Walnut Street
Suite 1015
Philadelphia, PA 19107

Telephone: 215-503-7801

A major focus of my current research is to develop the field of genetic counseling and genetic testing for prostate cancer which has a substantial heritable component. The ultimate goal of this research is to provide prostate cancer patients and their families with genetic information on inherited cancer risk to inform screening, treatment, and prevention approaches. My research studies encompass genetic characterization of cancer risk using sequencing technologies, molecular signatures, and novel biomarkers to ultimately reduce cancer-related morbidity and mortality.  Studies also focus on disparities in cancer risk assessment as well as behavioral factors impacting genetic counseling for men.

Research Projects

Genetic Evaluation of Men (GEM) Registry

A registry of men with and at risk for prostate cancer to evaluate genetic and environmental determinants of inherited prostate cancer to inform genetic testing for prostate cancer. Data collection includes medical history, family history, behavioral data as well as DNA for research.

Multigene panel testing sub-study of the GEM Registry

Offers a clinically available 25-cancer gene test to men with and at risk for prostate cancer. The goal is to evaluate the spectrum of variants in prostate cancer using clinically-validated methods.

Cancer Genetics Risk Registry

A registry of patients with any cancer or at-risk individuals evaluated for genetic risk.  Data collection includes  medical, family history, behavioral data as well as DNA for cancer risk research.

Molecular Screening for Lynch Syndrome in Upper Tract Urothelial Cancer

A study to determine if tumor tissue testing (immunohistochemistry) of upper tract urothelial biopsies can be used to identify patients who may have Lynch Syndrome and describe correlating genetic test results.

Inherited Cancer Risk Evaluation – the ICARE Study

Assess genetic counseling and germline genetic testing of patients with specific mutations identified on tumor sequencing to characterize the germline genetic spectrum among these patients.